Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00. The company’s shares closed yesterday at DKK634.67.

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK750.00. The company’s shares closed last Friday at ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with a ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field ...

AS Heart Month reminds us of the critical need to protect our cardiovascular and metabolic health, Novo Nordisk Philippines and the Philippine College of Endocrinology, Diabetes and Metabolism (PCEDM) ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

February 18, 2025 Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences ...